David Fleischer
Concepts (472)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peanut Hypersensitivity | 58 | 2025 | 143 | 13.820 |
Why?
| | Food Hypersensitivity | 53 | 2026 | 164 | 10.610 |
Why?
| | Arachis | 45 | 2025 | 108 | 9.070 |
Why?
| | Allergens | 59 | 2026 | 384 | 8.400 |
Why?
| | Desensitization, Immunologic | 31 | 2025 | 89 | 6.040 |
Why?
| | Infant Nutritional Physiological Phenomena | 12 | 2025 | 149 | 2.800 |
Why?
| | Anaphylaxis | 13 | 2025 | 102 | 2.630 |
Why?
| | Immunoglobulin E | 34 | 2026 | 315 | 2.280 |
Why?
| | Diet | 18 | 2024 | 1273 | 2.220 |
Why?
| | Dermatitis, Atopic | 15 | 2025 | 321 | 1.930 |
Why?
| | Milk Hypersensitivity | 8 | 2024 | 18 | 1.540 |
Why?
| | Epinephrine | 6 | 2026 | 155 | 1.540 |
Why?
| | Transdermal Patch | 3 | 2020 | 15 | 1.390 |
Why?
| | Eosinophilic Esophagitis | 10 | 2021 | 330 | 1.380 |
Why?
| | Skin Tests | 20 | 2025 | 94 | 1.320 |
Why?
| | Egg Hypersensitivity | 12 | 2026 | 28 | 1.160 |
Why?
| | Plant Proteins | 4 | 2025 | 112 | 1.120 |
Why?
| | Esophagoscopy | 13 | 2022 | 221 | 1.090 |
Why?
| | Immunotherapy | 9 | 2024 | 653 | 1.070 |
Why?
| | Primary Prevention | 5 | 2022 | 220 | 1.060 |
Why?
| | Hypersensitivity | 4 | 2025 | 252 | 1.030 |
Why?
| | Infant | 48 | 2026 | 10034 | 1.020 |
Why?
| | Antigens, Plant | 7 | 2025 | 55 | 1.010 |
Why?
| | Anti-Allergic Agents | 6 | 2026 | 40 | 0.960 |
Why?
| | Humans | 174 | 2026 | 144759 | 0.920 |
Why?
| | Administration, Cutaneous | 11 | 2025 | 125 | 0.920 |
Why?
| | Gastrointestinal Diseases | 9 | 2019 | 216 | 0.910 |
Why?
| | Infant Formula | 4 | 2023 | 71 | 0.900 |
Why?
| | Child | 60 | 2025 | 22633 | 0.880 |
Why?
| | Child, Preschool | 40 | 2026 | 11787 | 0.860 |
Why?
| | Nut Hypersensitivity | 3 | 2010 | 5 | 0.820 |
Why?
| | Noncommunicable Diseases | 1 | 2023 | 19 | 0.800 |
Why?
| | Breast Feeding | 8 | 2023 | 448 | 0.780 |
Why?
| | Protein Hydrolysates | 3 | 2018 | 6 | 0.750 |
Why?
| | Eczema | 10 | 2022 | 66 | 0.730 |
Why?
| | Hypersensitivity, Immediate | 3 | 2023 | 40 | 0.710 |
Why?
| | Endoscopy, Gastrointestinal | 7 | 2022 | 237 | 0.690 |
Why?
| | Asthma | 9 | 2025 | 1767 | 0.690 |
Why?
| | Immune Tolerance | 9 | 2023 | 379 | 0.660 |
Why?
| | Esophageal Stenosis | 6 | 2015 | 57 | 0.610 |
Why?
| | Esophageal Neoplasms | 10 | 2022 | 347 | 0.590 |
Why?
| | Double-Blind Method | 15 | 2025 | 2029 | 0.590 |
Why?
| | Omalizumab | 4 | 2026 | 43 | 0.590 |
Why?
| | Schools | 4 | 2021 | 453 | 0.580 |
Why?
| | Female | 77 | 2026 | 78271 | 0.580 |
Why?
| | Nasal Sprays | 3 | 2026 | 6 | 0.500 |
Why?
| | Male | 65 | 2026 | 72315 | 0.490 |
Why?
| | Eosinophilia | 4 | 2013 | 221 | 0.470 |
Why?
| | Gastroenterology | 2 | 2015 | 189 | 0.470 |
Why?
| | Administration, Oral | 9 | 2022 | 847 | 0.460 |
Why?
| | Pneumonia, Viral | 4 | 2020 | 384 | 0.440 |
Why?
| | Coronavirus Infections | 4 | 2020 | 378 | 0.440 |
Why?
| | Lye | 1 | 2014 | 1 | 0.430 |
Why?
| | Caustics | 1 | 2014 | 6 | 0.430 |
Why?
| | Dilatation | 2 | 2014 | 72 | 0.420 |
Why?
| | Burns, Chemical | 1 | 2014 | 32 | 0.420 |
Why?
| | Endosonography | 1 | 2015 | 157 | 0.420 |
Why?
| | Adolescent | 25 | 2025 | 22428 | 0.400 |
Why?
| | Practice Guidelines as Topic | 9 | 2024 | 1560 | 0.400 |
Why?
| | Eggs | 3 | 2026 | 25 | 0.390 |
Why?
| | Barrett Esophagus | 3 | 2022 | 165 | 0.390 |
Why?
| | Feeding Behavior | 3 | 2019 | 684 | 0.390 |
Why?
| | Betacoronavirus | 3 | 2020 | 286 | 0.390 |
Why?
| | Food | 5 | 2024 | 149 | 0.370 |
Why?
| | Pandemics | 5 | 2020 | 1694 | 0.360 |
Why?
| | Environmental Exposure | 1 | 2017 | 588 | 0.360 |
Why?
| | Gastrointestinal Hemorrhage | 4 | 2007 | 136 | 0.350 |
Why?
| | Cattle | 4 | 2024 | 1000 | 0.340 |
Why?
| | Allergy and Immunology | 3 | 2020 | 42 | 0.340 |
Why?
| | Infant Food | 2 | 2023 | 64 | 0.330 |
Why?
| | Esophagus | 8 | 2019 | 261 | 0.320 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2020 | 1720 | 0.320 |
Why?
| | Milk Proteins | 3 | 2024 | 35 | 0.310 |
Why?
| | Treatment Outcome | 13 | 2025 | 11679 | 0.310 |
Why?
| | Adenocarcinoma | 5 | 2022 | 928 | 0.310 |
Why?
| | Allergists | 3 | 2020 | 13 | 0.310 |
Why?
| | United States | 24 | 2024 | 15966 | 0.310 |
Why?
| | Endoscopy | 7 | 2018 | 316 | 0.300 |
Why?
| | Biological Products | 2 | 2026 | 252 | 0.300 |
Why?
| | Risk | 5 | 2018 | 911 | 0.290 |
Why?
| | Young Adult | 14 | 2026 | 14105 | 0.280 |
Why?
| | Virtual Reality | 2 | 2021 | 77 | 0.280 |
Why?
| | Adult | 27 | 2026 | 40449 | 0.260 |
Why?
| | Capsule Endoscopy | 1 | 2007 | 25 | 0.260 |
Why?
| | Intestinal Diseases | 1 | 2007 | 43 | 0.260 |
Why?
| | Consensus | 5 | 2021 | 488 | 0.260 |
Why?
| | Enterocolitis | 2 | 2020 | 18 | 0.260 |
Why?
| | Severity of Illness Index | 6 | 2019 | 2925 | 0.250 |
Why?
| | Colonoscopy | 4 | 2014 | 261 | 0.250 |
Why?
| | Adrenal Cortex Hormones | 3 | 2017 | 478 | 0.250 |
Why?
| | Brazil | 2 | 2023 | 180 | 0.240 |
Why?
| | Capsules | 2 | 2005 | 43 | 0.240 |
Why?
| | Time Factors | 7 | 2020 | 7173 | 0.240 |
Why?
| | Egg Proteins | 1 | 2026 | 20 | 0.240 |
Why?
| | Rhinitis, Allergic, Seasonal | 1 | 2026 | 25 | 0.240 |
Why?
| | Rhinitis, Allergic | 3 | 2022 | 42 | 0.240 |
Why?
| | National Institute of Allergy and Infectious Diseases (U.S.) | 7 | 2019 | 25 | 0.230 |
Why?
| | Cross-Over Studies | 2 | 2026 | 601 | 0.230 |
Why?
| | Administration, Sublingual | 3 | 2016 | 12 | 0.220 |
Why?
| | Pregnancy | 9 | 2024 | 7190 | 0.220 |
Why?
| | Immunomodulation | 2 | 2018 | 101 | 0.210 |
Why?
| | Gastrointestinal Neoplasms | 3 | 2000 | 70 | 0.210 |
Why?
| | Canada | 3 | 2020 | 428 | 0.210 |
Why?
| | Age Factors | 7 | 2018 | 3333 | 0.210 |
Why?
| | Follow-Up Studies | 7 | 2020 | 5408 | 0.200 |
Why?
| | Healthy Volunteers | 2 | 2024 | 215 | 0.200 |
Why?
| | Diagnostic Imaging | 2 | 2006 | 338 | 0.200 |
Why?
| | Constipation | 1 | 2024 | 98 | 0.190 |
Why?
| | Eosinophils | 2 | 2018 | 316 | 0.190 |
Why?
| | Catheter Ablation | 2 | 2019 | 353 | 0.190 |
Why?
| | Laser Therapy | 5 | 1985 | 135 | 0.190 |
Why?
| | Middle Aged | 23 | 2026 | 35875 | 0.180 |
Why?
| | Intestinal Mucosa | 2 | 2015 | 676 | 0.180 |
Why?
| | Animals | 14 | 2026 | 38058 | 0.180 |
Why?
| | Food Analysis | 1 | 2022 | 24 | 0.180 |
Why?
| | Point-of-Care Testing | 1 | 2022 | 35 | 0.180 |
Why?
| | Gastroesophageal Reflux | 2 | 2022 | 236 | 0.180 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 2115 | 0.170 |
Why?
| | Milk | 3 | 2018 | 119 | 0.170 |
Why?
| | Child Day Care Centers | 1 | 2021 | 44 | 0.170 |
Why?
| | Dietary Exposure | 1 | 2020 | 8 | 0.170 |
Why?
| | Aptamers, Nucleotide | 1 | 2022 | 85 | 0.170 |
Why?
| | Restaurants | 1 | 2020 | 22 | 0.160 |
Why?
| | Diet Therapy | 2 | 2017 | 37 | 0.160 |
Why?
| | Infusions, Subcutaneous | 1 | 2020 | 24 | 0.160 |
Why?
| | Deglutition Disorders | 2 | 2019 | 147 | 0.160 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2020 | 117 | 0.160 |
Why?
| | Immunization | 3 | 2017 | 374 | 0.150 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1489 | 0.150 |
Why?
| | Inservice Training | 1 | 2020 | 117 | 0.150 |
Why?
| | Europe | 2 | 2022 | 412 | 0.150 |
Why?
| | Respiratory Tract Infections | 1 | 2024 | 397 | 0.150 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2024 | 675 | 0.150 |
Why?
| | Multiphasic Screening | 1 | 2018 | 1 | 0.140 |
Why?
| | Prevalence | 4 | 2024 | 2834 | 0.140 |
Why?
| | Meta-Analysis as Topic | 2 | 2016 | 174 | 0.140 |
Why?
| | Confidence Intervals | 1 | 2019 | 333 | 0.140 |
Why?
| | Quality of Life | 6 | 2022 | 3185 | 0.140 |
Why?
| | Population Groups | 1 | 2018 | 58 | 0.140 |
Why?
| | United Kingdom | 4 | 2020 | 338 | 0.140 |
Why?
| | Blood Pressure | 1 | 2025 | 1769 | 0.140 |
Why?
| | Food, Genetically Modified | 1 | 2017 | 2 | 0.130 |
Why?
| | Coal Tar | 1 | 2017 | 2 | 0.130 |
Why?
| | Skin Cream | 1 | 2017 | 11 | 0.130 |
Why?
| | Keratolytic Agents | 1 | 2017 | 5 | 0.130 |
Why?
| | Plants, Genetically Modified | 1 | 2017 | 15 | 0.130 |
Why?
| | Emollients | 1 | 2017 | 11 | 0.130 |
Why?
| | Baths | 1 | 2017 | 13 | 0.130 |
Why?
| | Phosphodiesterase 4 Inhibitors | 1 | 2017 | 12 | 0.130 |
Why?
| | Histamine Antagonists | 1 | 2017 | 20 | 0.130 |
Why?
| | Crops, Agricultural | 1 | 2017 | 31 | 0.130 |
Why?
| | Clothing | 1 | 2017 | 23 | 0.130 |
Why?
| | Health Promotion | 1 | 2024 | 774 | 0.130 |
Why?
| | Ambulatory Care Facilities | 1 | 2020 | 265 | 0.130 |
Why?
| | Monitoring, Physiologic | 2 | 1990 | 289 | 0.130 |
Why?
| | Calcineurin Inhibitors | 1 | 2017 | 69 | 0.130 |
Why?
| | School Health Services | 1 | 2020 | 224 | 0.130 |
Why?
| | Mothers | 1 | 2023 | 775 | 0.120 |
Why?
| | Telemedicine | 3 | 2020 | 945 | 0.120 |
Why?
| | Risk Assessment | 4 | 2019 | 3671 | 0.120 |
Why?
| | Basophils | 2 | 2015 | 52 | 0.120 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 132 | 0.120 |
Why?
| | Nutritionists | 1 | 2016 | 24 | 0.120 |
Why?
| | Eating | 1 | 2019 | 389 | 0.120 |
Why?
| | Prognosis | 2 | 2020 | 4282 | 0.120 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 106 | 0.120 |
Why?
| | Kidney Transplantation | 1 | 2022 | 704 | 0.120 |
Why?
| | Bottle Feeding | 1 | 2016 | 19 | 0.120 |
Why?
| | Indonesia | 1 | 2015 | 23 | 0.120 |
Why?
| | Infant, Newborn | 6 | 2024 | 6429 | 0.120 |
Why?
| | Health Care Reform | 2 | 1994 | 109 | 0.120 |
Why?
| | Surveys and Questionnaires | 7 | 2024 | 6048 | 0.120 |
Why?
| | Nutritional Requirements | 1 | 2016 | 76 | 0.120 |
Why?
| | Decision Support Techniques | 1 | 2020 | 456 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2022 | 1166 | 0.110 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2015 | 34 | 0.110 |
Why?
| | Sublingual Immunotherapy | 1 | 2015 | 4 | 0.110 |
Why?
| | Probiotics | 1 | 2015 | 61 | 0.110 |
Why?
| | Carcinoma in Situ | 1 | 2015 | 44 | 0.110 |
Why?
| | Fluticasone | 1 | 2015 | 53 | 0.110 |
Why?
| | Injections, Intramuscular | 2 | 2026 | 141 | 0.110 |
Why?
| | History, 21st Century | 1 | 2015 | 219 | 0.110 |
Why?
| | Palliative Care | 4 | 2010 | 1002 | 0.110 |
Why?
| | Aging | 1 | 2005 | 1966 | 0.110 |
Why?
| | Guideline Adherence | 1 | 2019 | 589 | 0.110 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2015 | 641 | 0.110 |
Why?
| | History, 20th Century | 1 | 2015 | 325 | 0.100 |
Why?
| | Biopsy | 5 | 2019 | 1075 | 0.100 |
Why?
| | Coloring Agents | 2 | 2015 | 93 | 0.100 |
Why?
| | Wrist Injuries | 1 | 2014 | 23 | 0.100 |
Why?
| | Cumulative Trauma Disorders | 1 | 2014 | 30 | 0.100 |
Why?
| | Premedication | 3 | 1990 | 42 | 0.100 |
Why?
| | Anti-Bacterial Agents | 3 | 2017 | 1907 | 0.100 |
Why?
| | Risk Factors | 7 | 2019 | 10779 | 0.100 |
Why?
| | Wrist Joint | 1 | 2014 | 71 | 0.100 |
Why?
| | Occupational Injuries | 1 | 2014 | 46 | 0.100 |
Why?
| | Information Systems | 1 | 1993 | 57 | 0.100 |
Why?
| | Prospective Studies | 8 | 2019 | 7990 | 0.100 |
Why?
| | Physicians | 2 | 2020 | 939 | 0.100 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 634 | 0.100 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 732 | 0.100 |
Why?
| | Epitopes | 2 | 2025 | 485 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2020 | 947 | 0.100 |
Why?
| | Family | 2 | 2015 | 679 | 0.100 |
Why?
| | Posture | 2 | 2014 | 196 | 0.100 |
Why?
| | Patient Education as Topic | 2 | 2015 | 780 | 0.090 |
Why?
| | Sympathomimetics | 1 | 2012 | 19 | 0.090 |
Why?
| | Caregivers | 2 | 2020 | 1049 | 0.090 |
Why?
| | Societies, Medical | 2 | 1994 | 887 | 0.090 |
Why?
| | Mucositis | 1 | 2012 | 20 | 0.090 |
Why?
| | Disease Progression | 5 | 2019 | 2847 | 0.090 |
Why?
| | Poisson Distribution | 1 | 2012 | 78 | 0.090 |
Why?
| | Pregnenediones | 1 | 2012 | 14 | 0.090 |
Why?
| | Recurrence | 3 | 2004 | 1135 | 0.090 |
Why?
| | Health Surveys | 2 | 2012 | 518 | 0.090 |
Why?
| | Patient Compliance | 2 | 2016 | 588 | 0.090 |
Why?
| | Disease Management | 3 | 2024 | 645 | 0.090 |
Why?
| | Oximetry | 2 | 1990 | 126 | 0.090 |
Why?
| | Cohort Studies | 5 | 2022 | 5960 | 0.090 |
Why?
| | Self Care | 1 | 2014 | 389 | 0.080 |
Why?
| | Child Development | 1 | 2016 | 484 | 0.080 |
Why?
| | Stents | 3 | 2000 | 556 | 0.080 |
Why?
| | Patient Satisfaction | 1 | 2015 | 704 | 0.080 |
Why?
| | Biomarkers | 2 | 2020 | 4271 | 0.080 |
Why?
| | Bacterial Proteins | 1 | 2017 | 955 | 0.080 |
Why?
| | Feeding and Eating Disorders of Childhood | 1 | 2010 | 6 | 0.080 |
Why?
| | Symptom Assessment | 1 | 2012 | 137 | 0.080 |
Why?
| | Metaplasia | 2 | 2022 | 57 | 0.080 |
Why?
| | Curriculum | 1 | 2017 | 1059 | 0.080 |
Why?
| | Immunoassay | 1 | 2010 | 109 | 0.080 |
Why?
| | Health Policy | 1 | 1993 | 400 | 0.080 |
Why?
| | Cathartics | 1 | 1990 | 15 | 0.080 |
Why?
| | Citrates | 1 | 1990 | 41 | 0.080 |
Why?
| | Flavoring Agents | 1 | 1990 | 11 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1356 | 0.080 |
Why?
| | Phenotype | 1 | 2018 | 3162 | 0.080 |
Why?
| | Regression Analysis | 1 | 2012 | 1003 | 0.080 |
Why?
| | Immunologic Factors | 2 | 2022 | 255 | 0.080 |
Why?
| | Diet Surveys | 2 | 2024 | 91 | 0.080 |
Why?
| | Duodenoscopy | 1 | 1989 | 8 | 0.080 |
Why?
| | Adaptation, Psychological | 1 | 2015 | 717 | 0.080 |
Why?
| | Gastroscopy | 1 | 1989 | 18 | 0.070 |
Why?
| | Epithelial Cells | 2 | 2014 | 1125 | 0.070 |
Why?
| | Food, Formulated | 1 | 2009 | 15 | 0.070 |
Why?
| | Drainage | 1 | 2010 | 185 | 0.070 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2013 | 365 | 0.070 |
Why?
| | Lasers | 3 | 1985 | 132 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1217 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2024 | 17066 | 0.070 |
Why?
| | Physician-Patient Relations | 1 | 1993 | 585 | 0.070 |
Why?
| | Maternal Exposure | 1 | 2010 | 213 | 0.070 |
Why?
| | Light Coagulation | 1 | 1988 | 10 | 0.070 |
Why?
| | Physical Examination | 1 | 2009 | 239 | 0.070 |
Why?
| | Precancerous Conditions | 2 | 2019 | 166 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 985 | 0.060 |
Why?
| | Cholestasis | 1 | 2010 | 219 | 0.060 |
Why?
| | Digestive System | 2 | 2002 | 28 | 0.060 |
Why?
| | Hypnotics and Sedatives | 1 | 1989 | 216 | 0.060 |
Why?
| | Feces | 1 | 1990 | 513 | 0.060 |
Why?
| | Risk Reduction Behavior | 2 | 2019 | 226 | 0.060 |
Why?
| | Ovomucin | 1 | 2026 | 9 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1519 | 0.060 |
Why?
| | Aged | 15 | 2019 | 25913 | 0.060 |
Why?
| | Immunologic Tests | 1 | 2005 | 15 | 0.060 |
Why?
| | Remission, Spontaneous | 1 | 2005 | 40 | 0.060 |
Why?
| | Sepsis | 2 | 1989 | 640 | 0.060 |
Why?
| | Comorbidity | 2 | 2025 | 1658 | 0.060 |
Why?
| | Equipment Safety | 1 | 2005 | 38 | 0.060 |
Why?
| | Equipment Design | 2 | 2005 | 530 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3409 | 0.060 |
Why?
| | Anti-Inflammatory Agents | 1 | 2009 | 474 | 0.060 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1985 | 0.050 |
Why?
| | Dietetics | 2 | 2017 | 24 | 0.050 |
Why?
| | Esophageal and Gastric Varices | 1 | 1985 | 36 | 0.050 |
Why?
| | Administration, Intranasal | 1 | 2024 | 93 | 0.050 |
Why?
| | Immunoglobulin G | 3 | 2014 | 893 | 0.050 |
Why?
| | Procainamide | 1 | 1984 | 6 | 0.050 |
Why?
| | Hyperplasia | 2 | 2022 | 174 | 0.050 |
Why?
| | Nutrition Assessment | 1 | 2024 | 92 | 0.050 |
Why?
| | Therapeutic Irrigation | 1 | 1984 | 69 | 0.050 |
Why?
| | Pollen | 1 | 2023 | 19 | 0.050 |
Why?
| | Intestinal Absorption | 1 | 1984 | 103 | 0.050 |
Why?
| | Excipients | 1 | 2023 | 54 | 0.050 |
Why?
| | Turkey | 1 | 2022 | 19 | 0.050 |
Why?
| | Digestive System Diseases | 1 | 2002 | 27 | 0.050 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2024 | 181 | 0.050 |
Why?
| | Vitamins | 1 | 2024 | 178 | 0.050 |
Why?
| | Immunity | 1 | 2023 | 139 | 0.050 |
Why?
| | Delphi Technique | 1 | 2024 | 329 | 0.050 |
Why?
| | Metals | 2 | 2000 | 142 | 0.050 |
Why?
| | Software | 1 | 2007 | 690 | 0.050 |
Why?
| | Hemoglobinuria, Paroxysmal | 1 | 2002 | 7 | 0.040 |
Why?
| | Heart Rate | 1 | 2026 | 855 | 0.040 |
Why?
| | HLA Antigens | 1 | 2022 | 225 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4557 | 0.040 |
Why?
| | Respiratory Sounds | 1 | 2021 | 105 | 0.040 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2020 | 27 | 0.040 |
Why?
| | Educational Personnel | 1 | 2020 | 11 | 0.040 |
Why?
| | Injections | 1 | 2021 | 196 | 0.040 |
Why?
| | Terbutaline | 1 | 2020 | 8 | 0.040 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2002 | 219 | 0.040 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2000 | 15 | 0.040 |
Why?
| | Japan | 1 | 2000 | 143 | 0.040 |
Why?
| | Cholestasis, Intrahepatic | 1 | 2000 | 29 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 2021 | 182 | 0.040 |
Why?
| | Albuterol | 1 | 2020 | 73 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2020 | 65 | 0.040 |
Why?
| | China | 1 | 2000 | 269 | 0.040 |
Why?
| | Interprofessional Relations | 2 | 1994 | 281 | 0.040 |
Why?
| | Food Contamination | 1 | 2019 | 56 | 0.040 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2018 | 76 | 0.040 |
Why?
| | Medical History Taking | 1 | 2019 | 117 | 0.040 |
Why?
| | Esophagogastric Junction | 1 | 2019 | 55 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 573 | 0.040 |
Why?
| | Intestines | 1 | 2002 | 358 | 0.040 |
Why?
| | Health Planning Guidelines | 1 | 2018 | 24 | 0.030 |
Why?
| | Ischemia | 1 | 2002 | 421 | 0.030 |
Why?
| | New Zealand | 1 | 2018 | 54 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2363 | 0.030 |
Why?
| | Efferent Pathways | 1 | 1998 | 19 | 0.030 |
Why?
| | Food Labeling | 1 | 2017 | 13 | 0.030 |
Why?
| | Psychometrics | 1 | 2022 | 734 | 0.030 |
Why?
| | Locus Coeruleus | 1 | 1998 | 24 | 0.030 |
Why?
| | Hydrolysis | 1 | 2018 | 199 | 0.030 |
Why?
| | Markov Chains | 1 | 2018 | 129 | 0.030 |
Why?
| | Early Medical Intervention | 1 | 2018 | 61 | 0.030 |
Why?
| | Cross Reactions | 1 | 2017 | 130 | 0.030 |
Why?
| | Immune Sera | 1 | 2017 | 77 | 0.030 |
Why?
| | Skin Irritancy Tests | 1 | 2017 | 3 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2021 | 380 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2019 | 140 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2019 | 539 | 0.030 |
Why?
| | Metiamide | 1 | 1977 | 1 | 0.030 |
Why?
| | Australia | 1 | 2018 | 286 | 0.030 |
Why?
| | RNA, Viral | 1 | 2021 | 688 | 0.030 |
Why?
| | Thiourea | 1 | 1977 | 41 | 0.030 |
Why?
| | Agranulocytosis | 1 | 1977 | 30 | 0.030 |
Why?
| | Guanidines | 1 | 1977 | 41 | 0.030 |
Why?
| | Societies, Scientific | 1 | 2017 | 49 | 0.030 |
Why?
| | Norepinephrine | 1 | 1998 | 196 | 0.030 |
Why?
| | Nutritional Sciences | 1 | 2017 | 38 | 0.030 |
Why?
| | Antibody Specificity | 1 | 2017 | 181 | 0.030 |
Why?
| | Protective Factors | 1 | 2017 | 99 | 0.030 |
Why?
| | Uncertainty | 1 | 2017 | 144 | 0.030 |
Why?
| | Transgenes | 1 | 2017 | 189 | 0.030 |
Why?
| | Probability | 1 | 2017 | 310 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2017 | 197 | 0.030 |
Why?
| | Drug Dosage Calculations | 1 | 2016 | 27 | 0.030 |
Why?
| | Incidence | 2 | 2019 | 2879 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 2016 | 164 | 0.030 |
Why?
| | Imidazoles | 1 | 1977 | 254 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 2273 | 0.030 |
Why?
| | Iodides | 1 | 2015 | 11 | 0.030 |
Why?
| | Radio Waves | 1 | 2015 | 28 | 0.030 |
Why?
| | Mouth | 1 | 2015 | 88 | 0.030 |
Why?
| | Endoscopes | 2 | 1985 | 17 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1982 | 0.030 |
Why?
| | Calpain | 1 | 2014 | 61 | 0.030 |
Why?
| | Mass Screening | 2 | 2019 | 1347 | 0.030 |
Why?
| | Mice | 1 | 2011 | 18339 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 307 | 0.030 |
Why?
| | Treatment Failure | 1 | 2015 | 365 | 0.030 |
Why?
| | Synapses | 1 | 1998 | 439 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2012 | 2947 | 0.030 |
Why?
| | Steroids | 1 | 2014 | 160 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 312 | 0.030 |
Why?
| | Interleukin-13 | 1 | 2014 | 144 | 0.020 |
Why?
| | Population Surveillance | 1 | 2017 | 485 | 0.020 |
Why?
| | Public Opinion | 1 | 1993 | 60 | 0.020 |
Why?
| | Eosinophil Granule Proteins | 1 | 2012 | 15 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2000 | 823 | 0.020 |
Why?
| | Lysophospholipase | 1 | 2012 | 10 | 0.020 |
Why?
| | Haplotypes | 1 | 2014 | 490 | 0.020 |
Why?
| | Aged, 80 and over | 5 | 2010 | 8265 | 0.020 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2012 | 23 | 0.020 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1137 | 0.020 |
Why?
| | Forecasting | 1 | 1994 | 391 | 0.020 |
Why?
| | Biomedical Research | 1 | 2018 | 710 | 0.020 |
Why?
| | Mucous Membrane | 1 | 2012 | 127 | 0.020 |
Why?
| | Models, Genetic | 1 | 2014 | 536 | 0.020 |
Why?
| | Movement | 1 | 2014 | 293 | 0.020 |
Why?
| | Survival Rate | 2 | 2010 | 2089 | 0.020 |
Why?
| | Range of Motion, Articular | 1 | 2014 | 421 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 851 | 0.020 |
Why?
| | Abdominal Pain | 2 | 2002 | 146 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 885 | 0.020 |
Why?
| | Specimen Handling | 1 | 2012 | 186 | 0.020 |
Why?
| | Professional Role | 1 | 2012 | 158 | 0.020 |
Why?
| | Mutation | 1 | 2022 | 4089 | 0.020 |
Why?
| | Joint Commission on Accreditation of Healthcare Organizations | 1 | 1990 | 8 | 0.020 |
Why?
| | Age of Onset | 1 | 2012 | 551 | 0.020 |
Why?
| | Glycoproteins | 1 | 2012 | 355 | 0.020 |
Why?
| | Biomechanical Phenomena | 1 | 2014 | 842 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2012 | 769 | 0.020 |
Why?
| | Gallbladder Neoplasms | 1 | 2010 | 20 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2022 | 2919 | 0.020 |
Why?
| | Midazolam | 1 | 1990 | 72 | 0.020 |
Why?
| | Citric Acid | 1 | 1990 | 34 | 0.020 |
Why?
| | Endocarditis, Bacterial | 1 | 1989 | 44 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 206 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1833 | 0.020 |
Why?
| | Computer Simulation | 1 | 2014 | 1025 | 0.020 |
Why?
| | Genetic Variation | 1 | 2014 | 983 | 0.020 |
Why?
| | Health Status | 1 | 2014 | 836 | 0.020 |
Why?
| | Cholangiocarcinoma | 1 | 2010 | 105 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 5868 | 0.020 |
Why?
| | Neurons | 1 | 1998 | 1640 | 0.020 |
Why?
| | Bile Duct Neoplasms | 1 | 2010 | 127 | 0.020 |
Why?
| | Pancreatic Neoplasms | 2 | 2010 | 919 | 0.020 |
Why?
| | Pneumoperitoneum | 1 | 1988 | 12 | 0.020 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 1988 | 19 | 0.020 |
Why?
| | Electrocoagulation | 1 | 1987 | 36 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2014 | 1406 | 0.020 |
Why?
| | Social Support | 1 | 2012 | 652 | 0.020 |
Why?
| | Cell Movement | 1 | 2012 | 965 | 0.020 |
Why?
| | Anxiety | 1 | 2015 | 1109 | 0.020 |
Why?
| | Anesthesiology | 1 | 1990 | 175 | 0.020 |
Why?
| | Electrocardiography | 1 | 1990 | 662 | 0.020 |
Why?
| | Pediatrics | 1 | 2015 | 1114 | 0.020 |
Why?
| | Gastrostomy | 1 | 1988 | 130 | 0.020 |
Why?
| | Stress, Psychological | 1 | 2015 | 1152 | 0.020 |
Why?
| | Parents | 1 | 2015 | 1403 | 0.010 |
Why?
| | Duodenal Ulcer | 1 | 1985 | 12 | 0.010 |
Why?
| | Genetic Markers | 1 | 2006 | 331 | 0.010 |
Why?
| | Drug Design | 1 | 2006 | 173 | 0.010 |
Why?
| | Arteriovenous Malformations | 1 | 1985 | 29 | 0.010 |
Why?
| | Hemostatic Techniques | 1 | 1985 | 51 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1985 | 166 | 0.010 |
Why?
| | Random Allocation | 1 | 1985 | 363 | 0.010 |
Why?
| | Electrolytes | 1 | 1984 | 55 | 0.010 |
Why?
| | Stomach Neoplasms | 1 | 1985 | 126 | 0.010 |
Why?
| | Health Services Accessibility | 1 | 2012 | 1098 | 0.010 |
Why?
| | Quinidine | 1 | 1983 | 5 | 0.010 |
Why?
| | Tablets | 1 | 1983 | 41 | 0.010 |
Why?
| | Cholelithiasis | 1 | 2002 | 36 | 0.010 |
Why?
| | Streptococcal Infections | 1 | 1985 | 168 | 0.010 |
Why?
| | Gallstones | 1 | 2002 | 35 | 0.010 |
Why?
| | Biliary Tract Neoplasms | 1 | 2002 | 30 | 0.010 |
Why?
| | Colonic Diseases | 1 | 1982 | 34 | 0.010 |
Why?
| | Iran | 1 | 2002 | 44 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2010 | 845 | 0.010 |
Why?
| | Jejunum | 1 | 2002 | 35 | 0.010 |
Why?
| | Pancreatitis | 1 | 2002 | 145 | 0.010 |
Why?
| | Duodenum | 1 | 2002 | 77 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 183 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2002 | 415 | 0.010 |
Why?
| | Dogs | 1 | 1982 | 437 | 0.010 |
Why?
| | Age Distribution | 1 | 2002 | 403 | 0.010 |
Why?
| | Rectal Neoplasms | 1 | 1982 | 156 | 0.010 |
Why?
| | Sex Distribution | 1 | 2002 | 386 | 0.010 |
Why?
| | Granulation Tissue | 1 | 2000 | 6 | 0.010 |
Why?
| | Pruritus | 1 | 2000 | 59 | 0.010 |
Why?
| | Foreign-Body Reaction | 1 | 2000 | 36 | 0.010 |
Why?
| | Equipment Failure Analysis | 1 | 2000 | 128 | 0.010 |
Why?
| | Acute Disease | 1 | 2002 | 1030 | 0.010 |
Why?
| | Aspirin | 1 | 1983 | 399 | 0.010 |
Why?
| | Axonal Transport | 1 | 1998 | 26 | 0.010 |
Why?
| | Neuropeptides | 1 | 1998 | 77 | 0.010 |
Why?
| | Fibrosis | 1 | 2000 | 548 | 0.010 |
Why?
| | Neurons, Afferent | 1 | 1998 | 102 | 0.010 |
Why?
| | Tracheoesophageal Fistula | 1 | 1997 | 38 | 0.010 |
Why?
| | Biocompatible Materials | 1 | 2000 | 435 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2000 | 1462 | 0.010 |
Why?
| | Brain Mapping | 1 | 1998 | 536 | 0.010 |
Why?
| | False Positive Reactions | 1 | 1988 | 121 | 0.000 |
Why?
| | Peptococcus | 1 | 1985 | 1 | 0.000 |
Why?
| | Radiography | 1 | 1988 | 844 | 0.000 |
Why?
| | Drinking | 1 | 1983 | 42 | 0.000 |
Why?
| | Deglutition | 1 | 1983 | 72 | 0.000 |
Why?
| | Esophagitis | 1 | 1983 | 66 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1987 | 1053 | 0.000 |
Why?
| | Pilot Projects | 1 | 1987 | 1886 | 0.000 |
Why?
|
|
Fleischer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|